Citations

Clear

22 citation(s) found for "Hall, Scott R".

Identification of Risk Factors for Acute Kidney Injury from Intravenous Ketorolac in Geriatric Trauma Patients
Hall, Scott T. , Mangram, Alicia J. , Barletta, Jeffrey F.

Mayo Clinic

World Journal of Surgery | September 22, 2021 | Volume: 46 | Issue: 1 | Pages: 98-103

10.1007/s00268-021-06320-z | PMID 34553259 Get It

AbstractBackgroundKetorolac is an effective analgesic but the potential for acute kidney injury (AKI) is concerning, particularly in geriatric “G‐60 trauma” patients. The objectives of this study are to report the incidence of AKI in patients who receive ketorolac, identify risk factors for AKI, and develop a risk factor‐guided algorithm for safe utilization.MethodsThis retrospective cohort study included trauma patients age 60 years and older who received intravenous ketorolac. The primary endpoint was the incidence of AKI.ResultsAmong 316 patients evaluated, the incidence of AKI was 2.5%. Patients with AKI received more nephrotoxins, had more comorbidities, and higher use of loop diuretics or vasopressors. Loop diuretic therapy and number of comorbidities were independent predictors of AKI.ConclusionsRisk for AKI with ketorolac was low, being more prevalent with comorbidities or receipt of loop diuretics.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Nesic, Ksenija , Kondrashova, Olga , Hurley, Rachel M. , McGehee, Cordelia D. , Ho, Gwo‐Yaw , Lieschke, Elizabeth , Dall, Genevieve , Bound, Nirashaa , Shield‐Artin, Kristy , Musafer, Ashan, Chai, Zi Qing, Ghamsari, Mohammad Reza Eftekhariyan , Harrell, Maria I., Kee, Damien , Olesen, Inger, McNally, Orla , Study, Australian Ovarian Cancer, DeFazio, Anna , Bowtell, David D.L. , Swisher, Elizabeth M. , Weroha, S. John , Nones, Kátia , Waddell, Nicola , Wakefield, Matthew J. , Scott, Clare L. , Ho, Gwo-Yaw , Ghamsari, Mohammad Reza Eftekhariyan , Kee, Damien , Fazio, Anna de , Swisher, Elizabeth M , Nones, Katia , Waddell, Nicola , Kaufmann, Scott H , Dobrovic, Alexander , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Bowtell, David D , Vandenberg, Cassandra J. , Radke, Marc R. , Traficante, Nadia , Kaufmann, Scott H.

Mayo Clinic

Cancer Research | July 28, 2021 | Volume: 81 | Issue: 18 | Pages: 4709-4722

10.1158/0008-5472.can-21-0774 | PMID 34321239 Get It

Abstract In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. RAD51C promoter methylation (meRAD51C) is detected at similar frequencies to mutations, yet its effects on PARPi responses remain unresolved. In this study, three HGSC patient-derived xenograft (PDX) models with methylation at most or all examined CpG sites in the RAD51C promoter show responses to PARPi. Both complete and heterogeneous methylation patterns were associated with RAD51C gene silencing and homologous recombination deficiency (HRD). PDX models lost meRAD51C following treatment with PARPi rucaparib or niraparib, where a single unmethylated copy of RAD51C was sufficient to drive PARPi resistance. Genomic copy number profiling of one of the PDX models using SNP arrays revealed that this resistance was acquired independently in two genetically distinct lineages. In a cohort of 12 patients with RAD51C-methylated HGSC, various patterns of meRAD51C were associated with genomic “scarring,” indicative of HRD history, but exhibited no clear correlations with clinical outcome. Differences in methylation stability under treatment pressure were also observed between patients, where one HGSC was found to maintain meRAD51C after six lines of therapy (four platinum-based), whereas another HGSC sample was found to have heterozygous meRAD51C and elevated RAD51C gene expression (relative to homozygous meRAD51C controls) after only neoadjuvant chemotherapy. As meRAD51C loss in a single gene copy was sufficient to cause PARPi resistance in PDX, methylation zygosity should be carefully assessed in previously treated patients when considering PARPi therapy. Significance: Homozygous RAD51C methylation is a positive predictive biomarker for sensitivity to PARP inhibitors, whereas a single unmethylated gene copy is sufficient to confer resistance.
Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Hurley, Rachel M. , McGehee, Cordelia D. , Nesic, Ksenija , Weiskittel, Taylor M. , Kelly, Rebecca L. , Venkatachalam, Annapoorna , Hou, Xiaonan , Pathoulas, Nicholas M. , Meng, X. Wei, Kondrashova, Olga , Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Becker, Marc A., Southey, Melissa S, Harding, Thomas C., McNeish, Iain A. , Wagner, Jill M., Wakefield, Matthew J. , Scott, Clare L. , Hendrickson, Andrea E. Wahner , Karnitz, Larry M., Swisher, Elizabeth M. , Weroha, S. John , Lin, Kevin K. , Dobrovic, Alexander , Ross, Christian A, Haluska, Paul , Kaufmann, Scott H , McNeish, Iain A , Swisher, Elizabeth M , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Correia, Cristina , Radke, Marc R. , Wong, Ee Ming , Lin, Kevin , Roß, Christian , Li, Hu , Kaufmann, Scott H.

Mayo Clinic

NAR Cancer | July 10, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/narcan/zcab028 | PMID 34316715 Get It

Abstract Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous recombination (HR) deficiency and PARPi sensitivity. For this study, the PARPi-sensitive patient-derived ovarian cancer xenograft PH039, which lacks HR gene mutations but harbors RAD51C promoter methylation, was selected for PARPi resistance by cyclical niraparib treatment in vivo. PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Transcriptional profiling throughout the course of resistance development showed widespread pathway level changes along with a marked increase in RAD51C mRNA, which reflected loss of RAD51C promoter methylation. Analysis of ovarian cancer samples from the ARIEL2 Part 1 clinical trial of rucaparib monotherapy likewise indicated an association between loss of RAD51C methylation prior to on-study biopsy and limited response. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.
Sublesional Bevacizumab Injection for Recurrent Respiratory Papillomatosis: Evaluation of Utility in a Typical Clinical Practice
Hall, S. , Thiriveedi, Mrudula , Yandrapalli, Usha , Zhang, Nan , Yendrapalli, U. , Hall, Scott R , Lott, David G , Lott, David G.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | March 2, 2021 | Volume: 130 | Issue: 10 | Pages: 1164-1170

10.1177/0003489421998215 | PMID 33648353 Get It

Objectives: The goal of this study was to evaluate the benefit of sublesional bevacizumab injection for recurrent respiratory papillomatosis (RRP) as used in a typical clinical practice. Methods: A retrospective review of patients with RRP treated between 2011 and 2016 was undertaken. All patients were treated with in-office potassium titanyl phosphate (KTP) laser photoablation. Sublesional bevacizumab injection was used based on joint patient-physician decision making. Papilloma burden was objectively measured on prior recordings by 2 blinded reviewers and described as vocal fold segments affected (VFSA) by papilloma. Each patient served as their own control by comparing times when bevacizumab was or was not used. Mixed model for longitudinal data was used to determine if the previous use of bevacizumab decreased the disease burden. Results: A total of 19 patients met inclusion criteria and all prior laryngoscopic exams were reviewed for VFSA as described above. The mean (SD) number of VFSA when bevacizumab was not used at the prior procedure was 15 (14) as compared to 8 (11) when bevacizumab was used. When adjusted for age, time from initial presentation and baseline disease burden, mixed model showed a decrease of 11 VFSA (95% CI 6.5, 15.5, P < .0001) when bevacizumab was used as compared to when bevacizumab was not used at the prior procedure. In mixed model analysis, there was not a significant association between bevacizumab dose used and VFSA at the subsequent visit ( P = .8). Conclusion: Using sublesional bevacizumab intermittently based on clinical findings appears to be effective in improving disease control. Papilloma burden is significantly decreased at the subsequent clinical follow-up following injection of sublesional bevacizumab. The beneficial effect of sublesional bevacizumab may be not be dose-dependent.
Diced Cartilage in Fibrin Glue for Dorsal Reconstruction as Part of Staged Paramedian Forehead Flap Reconstruction
Abdel‐Aty, Yassmeen , Prasad, Navin , Hall, S. , Howard, Brittany E. , Hall, Scott R

Mayo Clinic

Journal of Craniofacial Surgery | September 30, 2020 | Volume: 32 | Issue: 3 | Pages: 1140-1142

10.1097/scs.0000000000007161 | PMID 33003154 Get It

Abstract The use of diced cartilage grafting is a powerful tool during rhinoplasty for dorsal augmentation; however, its application to nasal structural reconstruction has rarely been reported. Here we present a unique technique for Mohs defect reconstruction combining diced cartilage graft for dorsal augmentation and a folded paramedian forehead flap for soft tissue. A 54-year-old female presented with recurrent basal cell carcinoma of the nose that had been previously resected 3 times in the past. This was treated with Mohs surgery resulting in a through and through nasal defect. This was reconstructed with a staged folded paramedian forehead flap with staged. Due to a loss of dorsal volume and definition creating an excess supratip break, a diced cartilage graft with fibrin glue and temporalis fascia was used for dorsal augmentation. The use of diced cartilage has regained popularity over the last 2 decades with multiple techniques utilizing diced cartilage alone, wrapped in fascia, covered in fascia, wrapped in oxidized methylcellulose, or solidified with fibrin glue. Literature describing the use of fibrin glue suggests that it improves wound healing by promoting cartilage growth, stabilization, and diffusion of nutrients to the graft. Its malleable nature allows for adjustments after the initial placement. This report demonstrates the viability of diced cartilage graft for dorsal augmentation with a paramedian forehead flap for nasal reconstruction. This technique can serve as a powerful tool for the nasal reconstructive surgeon needing scaffolding to rebuild and define the nasal dorsum.
American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems
Hall, S. , Neel, Gregory S., Howard, Brittany E. , Nagel, Thomas H. , Hayden, Richard E. , Hinni, Michael L., Hall, Scott R , Chang, Brent A. , Lott, David G. , Zhang, Nan

Mayo Clinic

Head & Neck | April 2, 2019 | Volume: 41 | Issue: 8 | Pages: 2716-2723

10.1002/hed.25749 | PMID 30939209 Get It

AbstractBackgroundThe American Joint Committee on Cancer (AJCC) eighth edition introduces a staging system specific for human papilloma virus positive oropharyngeal cancer with separate clinical (AJCC 8c) and pathological (AJCC 8p) criteria.MethodsIn this retrospective cohort study, preoperative imaging and pathology reports were used to stage patients based on the AJCC 8c and AJCC 8p criteria, respectively. The primary endpoint was agreement between AJCC 8c and AJCC 8p.ResultsA total of 213 patients met inclusion criteria. Kappa statistics showed poor agreement (κ = 0.3275) between AJCC 8c and AJCC 8p. In total, 30.3% of patient's preoperative AJCC 8c stage changed based on the postoperative pathologic staging (AJCC 8p) with 73.4% of those being upstaged.ConclusionThese data suggest that disagreement exists between AJCC 8c and AJCC 8p, in part due to the separate clinical and pathological staging criteria. This discrepancy should be considered as the new system is implemented.
Outcomes of orthotopic heart transplantation and left ventricular assist device in patients aged 65 years or more with end-stage heart failure
Harmon, David , Tecson, Kristen M. , Jamil, Aayla K. , Felius, Joost , Gonzalez‐Stawinski, Gonzalo V. , Joseph, Susan , Hall, Shelley , Harmon, David M , Hall, Shelley A

Mayo Clinic

Baylor University Medical Center Proceedings | March 28, 2019 | Volume: 32 | Issue: 2 | Pages: 177-180

10.1080/08998280.2019.1576095 | PMID 31191122 Get It

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Harrell, Maria I., Oza, Amit M. , Oaknin, Ana , Tinker, Anna V. , Helman, Elena , Radke, Marc R. , Say, Carmen , Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D., Maloney, Lara , O’Malley, David M. , Chambers, Setsuko K., Scott, Clare L. , Konecny, Gottfried E. , Giordano, Heidi, Harding, Thomas C., McNeish, Iain A. , Swisher, Elizabeth M. , Lin, Kevin K. , Kaufmann, Scott H , Brenton, James D , McNeish, Iain A , Swisher, Elizabeth M , Scott, Clare L , O'Malley, David M , Lin, Kevin , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Coleman, Robert L. , Sun, James X. , Brenton, James D.

Mayo Clinic

Cancer Discovery | November 13, 2018 | Volume: 9 | Issue: 2 | Pages: 210-219

10.1158/2159-8290.cd-18-0715 | PMID 30425037 Get It

Abstract A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P &lt; 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. Significance: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity. This article is highlighted in the In This Issue feature, p. 151
Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study
Hall, Lauren , Hagan, Michael , Sharma, Sushma, Yeramaneni, Samrat , Trotter, James F. , Talwalkar, Jayant A., Kanwal, Fasiha , Talwalkar, Jayant, Asrani, Sumeet K. , Hall, Lauren

Mayo Clinic

American Journal of Gastroenterology | October 17, 2018 | Volume: 114 | Issue: 1 | Pages: 98-106

10.1038/s41395-018-0365-4 | PMID 30333543 Get It

OBJECTIVES: In a population-based study, we examined time trends in chronic liver disease (CLD)-related hospitalizations in a large and diverse metroplex. METHODS: We examined all CLD-related inpatient encounters (2000–2015) in Dallas–Fort Worth (DFW) using data from the DFW council collaborative that captures claims data from 97% of all hospitalizations in DFW (10.7 million regional patients). RESULTS: There were 83,539 CLD-related hospitalizations in 48,580 unique patients across 84 hospitals. The age and gender standardized annual rate of CLD-related hospitalization increased from 48.9 per 100,000 in 2000 to 125.7 per 100,000 in 2014. Mean age at hospitalization increased from 54.0 (14.1) to 58.5 (13.5) years; the proportion of CLD patients above 65 years increased from 24.2% to 33.1%. HCV-related hospitalizations plateaued, whereas an increase was seen in hospitalizations related to alcohol (9.1 to 22.7 per 100,000) or fatty liver (1.4 per 100,000 to 19.5 per 100,000). The prevalence of medical comorbidities increased for CLD patients: coronary artery disease (4.8% to 14.3%), obesity (2.8% to 14.6%), chronic kidney disease (2.8% to 18.2%), and diabetes (18.0% to 33.2%). Overall hospitalizations with traditional complications of portal hypertension (ascites, varices, and peritonitis) remained stable over time. However, hospitalization with complications related to infection increased from 54.7% to 66.4%, and renal failure increased by sevenfold (2.7% to 19.5%). CONCLUSIONS: CLD-related hospitalizations have increased twofold over the last decade. Hospitalized CLD patients are older and sicker with multiple chronic conditions. Traditional complications of portal hypertension have been superseded by infection and renal failure, warranting a need to redefine what it means to have decompensated CLD.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, Olga , Nguyen, Minh , Shield‐Artin, Kristy , Tinker, Anna V. , Teng, Nelson N.H., Harrell, Maria I., Barker, Holly E. , Prakash, Rohit , Kass, Elizabeth M. , Sullivan, Meghan R. , Brunette, Gregory J. , Bernstein, Kara A. , Floquet, Anne , Friedländer, Michael , O’Malley, David M. , Oza, Amit M. , Robillard, Liliane, Maloney, Lara , Bowtell, David D.L. , Giordano, Heidi, Wakefield, Matthew J. , Simmons, Andrew D. , Harding, Thomas C., Raponi, Mitch , McNeish, Iain A. , Swisher, Elizabeth M. , Scott, Clare L. , Lin, Kevin K. , Kaufmann, Scott H. , Kuiper, Michael J. , Ho, Gwo‐Yaw , Jasin, Maria , Sullivan, Meghan R. , Coleman, Robert L. , Kichenadasse, Ganessan , Sun, James X. , Lin, Kevin , McNeish, Iain A , Swisher, Elizabeth M , Friedlander, Michael , Wakefield, Matthew J , Scott, Clare L , Bernstein, Kara A , Kondrashova, Olga , Bowtell, David D , Barker, Holly E , O'Malley, David M

Mayo Clinic

Cancer Discovery | June 6, 2017 | Volume: 7 | Issue: 9 | Pages: 984-998

10.1158/2159-8290.cd-17-0419 | PMID 28588062 Get It

Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations. Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984–98. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Quigley et al., p. 999. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920